Clinical Trial Update: Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies [NA]

View source ↗

Summary

A clinical trial investigating prophylactic TCRαβ+ and CD19+ depleted donor lymphocyte infusion after allogeneic stem cell transplant for high-risk hematologic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• TCRαβ+ and CD19+ depleted donor lymphocyte infusion

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Hematologic Malignancies | NA | Status: SUSPENDED